Mouse Osteoprotegerin,OPG ELISA KIT

最近的研究表明，TNFRSF11B在骨代谢和肿瘤的发生中起着重要作用。

Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

1. lactation increases physiological maxillary bone remodeling and orthodontic tooth movement, and both require activation of RANK/RANKL/OPG system PMID: 29382610
2. Hdac3-depletion in osteoblasts increases expression of Opg, subsequently preserving insulin sensitivity. PMID: 28840938
3. Epithelial rests of Malassez may be associated with root resorption via OPG, thus helping to explain the mechanism underlying root resorption. PMID: 29644561
4. findings demonstrate that mTORC1 activation-stimulated RANKL expression in B cells is sufficient to induce bone loss and osteoporosis. The study also established a link between mTORC1 and the RANKL/OPG axis via negative regulation of beta-catenin. PMID: 26825871
5. RANK/RANKL signaling is involved in the androgen deprivation therapy-induced acceleration of bone metastasis in castration-insensitive prostate cancer and is inhibited by osteoprotegerin to prevent bone metastasis. PMID: 28373003
6. endocortical resorption is driven by reduced OPG rather than elevated RANKL expression PMID: 27460899
7. Diabetes significantly increased OPG and the OPG/TRAIL ratio expression in the aorta, while dyslipidemia was the major determinant of the changes observed in the heart, where it significantly increased OPG and reduced TRAIL expression, thus increasing cardiac OPG/TRAIL ratio. PMID: 28070143
8. These discoveries strongly suggest that Heparan Sulfate plays an active role in regulating OPG-RANKL interaction and osteoclastogenesis. PMID: 27697839
9. OPG plays an important role in regulating bone marrow mesenchymal stem cells differentiation and bone marrow adipogenesis. PMID: 27898403
10. These data suggested that OPG played an important role in maintaining the homeostasis of articular cartilage of femoral head. PMID: 27541035
11. Data show that p38alpha mitogen-activated protein kinase (MAPK) in paired related homeobox 1 protein (Prx1+) bone marrow-derived mesenchymal stromal cells acts to preserve the bone by sustaining osteoprotegerin (OPG) production. PMID: 26947973
12. OPG expression in chondrocyte increases bone mass in the proximal metaphysis of tibiae through negative regulation of osteoclast formation. PMID: 26329493
13. the generation of Rag2GFP+ regulatory T cells is unaltered in Tnfrsf11b(-/-) mice PMID: 26254339
14. identify osteoprotegerin as a HIF target gene capable of directing osteoblast-mediated osteoclastogenesis to regulate bone homeostasis PMID: 25846796
15. Osteoprotegerin is increased in metabolic syndrome and promotes adipose tissue proinflammatory changes. PMID: 24998520
16. These results indicate that OPG derived either from the bone marrow or from the vessel wall is sufficient to slow down lesion progression and vascular calcification independent of bone turnover. PMID: 23990207
17. High concentrations of alendronate decrease the expressions of OPG and RANKL in cultured osteoblasts. PMID: 23268391
18. In a xenograft model, increased osteoprotegerin expression correlated with a delay to pathologic fracture suggesting a potential role for mTOR inhibitors in the treatment of neuroblastoma bone metastases. PMID: 23331792
19. Coptisine inhibits RANKL-induced NF-kappaB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells. PMID: 21656335
20. OPG gene transfer to periodontal tissues could inhibit relapse after orthodontic tooth movement, through the inhibition of osteoclastogenesis PMID: 22196183
21. Omentin-1 ameliorates arterial calcification and bone loss in vivo through the regulation of the RANK signalling pathway in osteoprotegerin-deficient mice. PMID: 21750093
22. Increased bone resorption is a noncell autonomous defect, caused by exuberant stimulation of osteo-clastogenesis by Cx43-deficient bone marrow stromal cells, via decreased Opg production. PMID: 21346198
23. Osteoprotegerin serum levels were decreased in all IL-6 deficient mice and in a highest degree in sham-operated hypothyroid mice. PMID: 21478097
24. TRAIL and osteoprotegerin are expressed in atherosclerotic plaques in a calcification-prone mouse model PMID: 21426505
25. RANKL and OPG could have a close relationship with the osteoclast activity during mandibular first molar eruption. PMID: 18788552
26. distribution of the osteocytic lacunar-canalicular system and osteocyte-secreting molecules--dentin matrix protein 1 and sclerostin--in the epiphyses and cortical bones in osteoprotegerin deficiency PMID: 21079361
27. overexpression in preosteoblasts promotes their differentiation into mature osteoblasts PMID: 20936961
28. Co2+ and Cr3+ can stimulate the mRNA expressions of RANKL and osteoprotegerin in osteoblasts. PMID: 20369527
29. mechanical stretching may play an important role in bone remodeling through the upregulation of OPG and the mechanical signaling leading to OPG induction involves the noncanonical Wnt pathway. PMID: 20200998
30. Osteoprotegerin(OPG) ex vivo gene therapy may be useful to treat patients for aseptic loosening of prosthetic implants. PMID: 11918293
31. expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells PMID: 12211438
32. Osteosclerosis in mice with thrombopoietin overexpression occurs predominantly via up-regulation of osteoprotegerin in host stromal cells leading to disruption of osteoclastogenesis. PMID: 12506018
33. The presence of OPG on the membrane of these cells was confirmed by western blotting and immunostaining, sRANKL was found to be bound to the OPG on the osteoclast precursors. PMID: 12526098
34. expression of RANKL and OPG change with age in whole bone and in cultured osteoblast-like cells PMID: 12568404
35. Runx2 promotes osteoclast differentiation by inducing RANKL and inhibiting OPG PMID: 12697767
36. osteoprotegerin and RANK ligand have roles in breast cancer bone metastasis PMID: 12923331
37. bone formation is coupled with bone resorption at local sites in OPG-/- mice, and that serum RANKL levels do not reflect this coupling. PMID: 14500574
38. OPG secretion is regulated through calmodulin-sensitive protein kinase signaling that depends on the activity of the L-type VSCC and is mediated through the cAMP response element-binding protein. PMID: 14525906
39. suppression of gene expression affects osteoclastogenic activity of parathyroid hormone PMID: 14969393
40. Expression in mice with collagen-induced arthritis treated with Kanzo-bushi-to, a Kampo medicine. PMID: 15340228
41. expression of RANKL and OPG and the formation of osteoclast-like cells do not require Runx2 PMID: 15474477
42. RANKL inhibitor osteoprotegerin is used to evaluate the role of osteoclast-mediated hypercalcemia in two murine models of hypercalcemia of malignancy. PMID: 15845617
43. Microorganism-reactive CD4+ T-cells and the RANKL-osteoprotegerin axis provide the molecular basis of the advanced periodontal breakdown in diabetes. PMID: 15855336
44. findings in OPG knockout mice support the hypothesis that OPG is important in the inhibition of bone remodeling within the otic capsule and the maintenance of normal auditory function PMID: 16467704
45. Glucocorticoids regulate osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones PMID: 16614077
46. OPG inhibits advanced plaque progression by preventing an increase in lesion size and lesion calcification. OPG may act as a survival factor and may modulate MMP9 production in vascular cells. PMID: 16840715
47. microgravity is capable to indirectly stimulate osteoclast formation and activity by regulating osteoblast secretion of crucial regulatory factors such as RANKL and OPG PMID: 16927271
48. Altogether, these findings suggest that increased OPG production represents an early event in the natural history of diabetes mellitus, possibly contributing to disease-associated endothelial cell dysfunction. PMID: 17148684
49. OPG suppresses the shedding of RANKL from osteoblasts and the serum RANKL in OPG(-/-) mice exactly reflects the state of bone resorption. PMID: 17182555
50. bone resorptive action of Dexamethasone is mediated mainly by the inhibition of OPG by transrepressing the OPG gene through the AP-1 site PMID: 17516544

显示更多

收起更多

Secreted.

Highly expressed in liver, lung, stomach, intestines and calvaria. Highly expressed in decidua and placenta, and in embryo.

KEGG: mmu:18383

STRING: 10090.ENSMUSP00000078705

UniGene: Mm.15383